Pharmaron
康龙化成
Executive Summary
Pharmaron is China's top-5 CRO/CDMO with ~$1.2B revenue, offering full-spectrum drug discovery to commercial manufacturing services. The company serves major pharma clients including J&J, Novartis, and AbbVie, positioning it as a critical service provider but also making it a prime target for BIOSECURE Act designation. Founded by Boliang Lou in 2004, Pharmaron is dual-listed on HK/Shenzhen exchanges and faces high regulatory risk following the December 2024 BIOSECURE Act signing.
Structure: Pharmaron operates through a standard mainland Chinese structure with the listed Hong Kong entity (3759.HK) controlling operating subsidiaries in mainland China. The Beijing operating subsidiary (Pharmaron Beijing Co., Ltd.) conducts the core CRO/CDMO business activities, creating direct BIOSECURE exposure through its comprehensive drug development services.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Boliang Lou 楼柏良 | Founder & Chairman | PhD, Columbia University |
Ownership & Shareholder Structure
Pharmaron → Johnson & Johnson
Boliang Lou (Pharmaron founder, Columbia PhD) — key J&J CRO relationship.
Pharmaron → Novartis
Pharmaron provides drug discovery and development services to Novartis.
Pharmaron → Porton Pharma Solutions
Both small molecule CDMOs competing for Big Pharma API manufacturing.
Subsidiaries & Affiliates(1)
| Entity | Type | Jurisdiction | Scope | Flags | BIOSECURE |
|---|---|---|---|---|---|
Pharmaron Beijing Co., Ltd. 北京康龙化成新药技术股份有限公司 | operating | mainland china | Drug discovery, development, and manufacturing services. Full CRO/CDMO spectrum. | CDMO | DIRECT |
Corporate Events
BIOSECURE Act signed — Pharmaron at risk
Pharmaron is a top-5 Chinese CRO/CDMO. Category B designation risk under OMB review.
BIOSECURE Impact: Direct risk. CRO/CDMO services to US clients make it a candidate for Category B designation.
BIOSECURE Risk
Top-5 Chinese CRO/CDMO status makes Pharmaron a likely candidate for Category B designation under OMB review process. The company's extensive US pharma client relationships and critical role in drug development supply chains elevate regulatory scrutiny.
Key Exposures:
- •Direct CRO/CDMO services to US pharma
- •Drug discovery and development capabilities
- •Manufacturing operations
- •Top-5 market position in China
Mitigation: No public mitigation strategy disclosed following BIOSECURE Act signing
BD Intelligence
Therapeutic Areas:
Recent Deals: Limited out-licensing activity as company focuses on service business model rather than proprietary drug development
Approach: Extreme caution advised - wait for OMB Category B designation outcome before any new partnership discussions. Existing relationships should be evaluated for compliance risk.
Red Flags
- ⚠High BIOSECURE designation risk
- ⚠Congressional pressure specifically targeting company
- ⚠Potential loss of US client base
- ⚠Regulatory compliance uncertainty for US partners
Quick Facts
- Key People
- 1
- Subsidiaries
- 1
- CDMO/CRO Subs
- 1
- Genomics Subs
- 0
- Direct BIOSECURE
- 1
- Corp Events
- 1
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 7
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: HKEX annual reports, HKEX Disclosure of Interests
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.